TVGN Stock Overview
Operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Tevogen Bio Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.34 |
| 52 Week High | US$21.09 |
| 52 Week Low | US$0.26 |
| Beta | -1.03 |
| 11 Month Change | -56.07% |
| 3 Month Change | 177.43% |
| 1 Year Change | -87.85% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -86.51% |
Recent News & Updates
Recent updates
Shareholder Returns
| TVGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.5% | 4.0% | 2.0% |
| 1Y | -87.9% | 18.0% | 32.4% |
Return vs Industry: TVGN underperformed the US Biotechs industry which returned 18.3% over the past year.
Return vs Market: TVGN underperformed the US Market which returned 32.6% over the past year.
Price Volatility
| TVGN volatility | |
|---|---|
| TVGN Average Weekly Movement | 60.5% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: TVGN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TVGN's weekly volatility has increased from 40% to 60% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 19 | Ryan Saadi | tevogen.com |
Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer.
Tevogen Bio Holdings Inc. Fundamentals Summary
| TVGN fundamental statistics | |
|---|---|
| Market cap | US$248.57m |
| Earnings (TTM) | -US$4.50m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-52.2x
P/E RatioIs TVGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TVGN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$4.50m |
| Earnings | -US$4.50m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.026 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -43.0% |
How did TVGN perform over the long term?
See historical performance and comparison